ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Gregory T. Armstrong, MD, MSCE, on Late Mortality in Childhood Cancer Survivors

Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discusses the findings of a landmark survivorship study (Abstract LBA2).

Skin Cancer

Claus Garbe, MD

Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma

Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).

Issues in Oncology

Cost of Care

Charles L. Bennett, MD, PhD, MPP and James O. Armitage, MD

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

Supportive Care

Symptom Management

Palliative Care

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Survivorship

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors

Lisa Diller, MD, of Dana-Farber Cancer Institute, and Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discuss the findings of a landmark survivorship study (Abstract LBA2).

Aug

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Gregory T. Armstrong, MD, MSCE, on Late Mortality in Childhood Cancer Survivors

Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume

Smoking Cessation in Cancer Care: Challenges and Opportunities

GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes

Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers